Last reviewed · How we verify
Prevention of systemic embolism
Approved treatments
- Dabigatran etexilate (DE) · Pfizer Inc.
Dabigatran etexilate (DE) as oral capsule - Pradaxa · Boehringer Ingelheim
Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development. - Pradaxa · Generic (originally Boehringer Ingelheim)
Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of systemic embolism patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of systemic embolism treatment landscape brief
- Prevention of systemic embolism treatment updates RSS
Frequently asked questions about Prevention of systemic embolism
What drugs treat Prevention of systemic embolism?
Tracked treatments include Dabigatran etexilate (DE), Pradaxa.
What is the treatment for Prevention of systemic embolism?
Standard treatment for Prevention of systemic embolism includes Dabigatran etexilate (DE), Pradaxa. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of systemic embolism patent cliff · Prevention of systemic embolism CI report
- Treatment: Dabigatran etexilate (DE) · Pfizer Inc.
- Treatment: Pradaxa · Boehringer Ingelheim
- Treatment: Pradaxa · Generic (originally Boehringer Ingelheim)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing